Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 46Lung Neoplasms 19Melanoma 18Neoplasm Metastasis 16Carcinoma, Hepatocellular 15Neoplasms 13Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Colorectal Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Stomach Neoplasms 6Rectal Neoplasms 6Esophageal Squamous Cell Carcinoma 6Carcinoma, Renal Cell 6Brain Neoplasms 6Small Cell Lung Carcinoma 5Recurrence 5Pancreatic Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Liver Neoplasms 4Glioblastoma 4Cholangiocarcinoma 4Prostatic Neoplasms 3Nasopharyngeal Carcinoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

Vincristine 2Temozolomide 2Oncolytic Virotherapy 2vorasidenib 1repotrectinib 1pralsetinib 1pembrolizumab 1pamiparib 1lutetium Lu 177 dotatate 1interferon gamma-1b 1copper dotatate CU-64 1cixutumumab 1Vorinostat 1Valproic Acid 1Thiotepa 1Sunitinib 1Radiotherapy 1Radiation 1Peripheral Blood Stem Cell Transplantation 1ONC206 1Melphalan 1Maintenance Chemotherapy 1Lutetium-177 1Lutetium 1Lomustine 1Interleukin-12 1Interferon-gamma 1Immunotherapy 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors × Immunotherapy × Clear all
NCT02197169 2018-07-16

TARGET-I

DNAtrix, Inc.

Phase 1 Completed
37 enrolled
CNSSarcoma

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡